In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Selecta Biosciences (SELB), with a price target of $7. The company’s shares opened today at $2.22, close to its 52-week low of $1.41.
“We are reiterating our Buy rating and $7 target price after SELB reported its 4Q18 financial and business update. While we believe SELB’s 1Q19 capital raise addressed some of the near-term headwinds for the stock and should allow the company to further develop its lead program, SEL-212, as a treatment for chronic severe gout, we do think the company must execute well in order to achieve its communicated timelines, which appear somewhat aggressive. As we published recently, the design of the H2H study (SEL-212 vs. Krystexxa) and the fact Krystexxa is being used as monotherapy may not fully resolve the investor debate around SEL-212’s commercial opportunity, even if results are positive. With that said, we remain encouraged after our discussion with management today in which it indicated securing a partnership for its ImmTOR platform remains a priority this year.”
According to TipRanks.com, Archila has 0 stars on 0-5 star ranking scale with an average return of -6.7% and a 36.0% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Pacira Pharmaceuticals, and Heron Therapeutics.
Selecta Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $9.70.
The company has a one-year high of $16.55 and a one-year low of $1.41. Currently, Selecta Biosciences has an average volume of 526.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The firm produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.